Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Eustace, Amanda, Irlam, Joely J., Taylor, Janet, Denley, Helen, Agrawal, Shailesh, Choudhury, Ananya, Ryder, David, Ord, Jonathan J., Harris, Adrian L., Rojas, Ana M., Hoskin, Peter J., West, Catharine M.L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier Scientific Publishers 2013
Schlagworte:
Phase III randomised trial
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://ncbi.nlm.nih.gov/pubmed/23773411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2013.05.017
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge